Key result
Cardiac lipid dysregulation drives heart failure via lipotoxicity and energetic depletion, revealing new metabolic targets.
Why the study?
Metabolic therapies targeting cardiac lipid metabolism remain underdeveloped and have largely failed for heart failure, despite the heart's critical reliance on balanced lipid uptake and utilization.
Provides a comprehensive overview of cardiac lipid metabolism regulation, highlighting potential avenues for novel metabolic therapies in heart failure.
Although studied for decades, metabolic therapies that target cardiac lipid metabolism are underdeveloped, and most approaches have thus far failed as a heart failure treatment. In contrast, new therapies for diabetes and obesity are widely used for the prevention and treatment of heart failure. The heart depends heavily on lipid uptake and utilization for proper function. Too much or too little cardiac lipid catabolism becomes detrimental and causes heart failure, either due to lipotoxicity or energetic depletion. For this reason, cardiac lipid metabolism is carefully controlled and balanced. Moreover, cardiac fatty acid oxidation affects systemic energy metabolism, as evidenced by changes in circulating levels of fatty acids and lipoproteins. This review describes mechanisms of regulation of lipid uptake and metabolism by cardiomyocytes, how fatty acid and glucose use are coordinated, how mitochondrial fatty acid metabolism is regulated at the transcriptional and posttranslational levels, as well as how fed/fasting cycles and circadian clocks modulate heart metabolism during the day. We review studies that used cultured cells, animal models, human tissue, and nuclear tracing. Our objective is to present current knowledge on mechanisms that control cardiac lipid metabolism, thereby suggesting experimental directions that could lead to new metabolic therapies.
No takes yet. Share an insight, caveat, or question.
Goldberg et al. (2026) conducted a review in Heart failure. Metabolic therapies targeting cardiac lipid metabolism was evaluated. Cardiac lipid metabolism is carefully controlled, and its dysregulation can cause heart failure due to lipotoxicity or energetic depletion, highlighting potential targets for new metabolic therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: